Stockscreener 앱 받기
1.45
0.69%
0.01
시장 영업 전:
1.45
Sunshine Biopharma Inc 주식(SBFM)의 최신 뉴스
Sunshine Biopharma (NASDAQ:SBFMW) Trading Down 3.8% – Here’s Why - Defense World
Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’ - MSN
Sunshine Biopharma Launches Generic Gabapentin for Neuropathic P - GuruFocus
Sunshine Biopharma launches generic anticonvulsant drug in Canada By Investing.com - Investing.com South Africa
Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’ By Stocktwits - Investing.com India
Sunshine Biopharma (SBFM) Expands Portfolio with New Gabapentin Launch | SBFM Stock News - GuruFocus
Sunshine Biopharma launches generic anticonvulsant drug in Canada - Investing.com
Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market - Yahoo Finance
Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees 'Huge Potential' - MENAFN.com
Sunshine Biopharma (NASDAQ:SBFMW) Trading 17.8% Higher – Here’s Why - Defense World
Sunshine Biopharma Sees 18% Revenue Growth in Q1 2025 - TipRanks
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues - GuruFocus
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year - ACCESS Newswire
Sunshine Biopharma Reports Double-Digit Growth: Q1 Revenue Jumps 18% as Pipeline Expands with 6 New Drugs - Stock Titan
Sunshine Biopharma (NASDAQ:SBFM) Stock Price Up 8% – Here’s Why - Defense World
Sunshine Biopharma launches generic antipsychotic drug - Investing.com Australia
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia - GuruFocus
Sunshine Biopharma (SBFM) Unveils Generic Antipsychotic Drug in Canada | SBFM Stock News - GuruFocus
Sunshine Biopharma launches generic antipsychotic drug By Investing.com - Investing.com Canada
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market - ACCESS Newswire
Sunshine Biopharma Challenges $1.2B Antipsychotic Market With New Generic Latuda Alternative - Stock Titan
Certain Warrants of Sunshine Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2025. - marketscreener.com
Sunshine Biopharma Inc’s Market Journey: Closing Weak at 1.84, Down -18.22 - DWinneX
Sunshine Biopharma (NASDAQ:SBFMW) Stock Price Down 4.5% – Here’s Why - Defense World
There is no doubt that Sunshine Biopharma Inc (SBFM) ticks all the boxes. - Sete News
Sunshine Becomes Latest To Compete On Everolimus In Canada - insights.citeline.com
Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug - Asianet Newsable
Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug By Stocktwits - Investing.com India
SBFM Stock: A Comprehensive Analysis and Forecast - investchronicle.com
Sunshine Biopharma enters Canadian generic drug market with Everolimus By Investing.com - Investing.com South Africa
Press Release Distribution & PR Platform - ACCESS Newswire
SBFM’s valuation metrics: A comprehensive analysis - uspostnews.com
Sunshine Biopharma (SBFM) Finalizes $2.46 Million Stock Offering - GuruFocus
Sunshine Biopharma Unit Rolls Out Afinitor Alternative Everolimus in Canadian Market - marketscreener.com
Sunshine Biopharma enters Canadian generic drug market with Everolimus - Investing.com
Sunshine Biopharma (SBFM) Launches Generic Everolimus in Canada | SBFM Stock News - GuruFocus
Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion | SBFM Stock News - GuruFocus
Major Cancer Treatment Everolimus Enters Canadian Market: Multiple Cancer Types Targeted in $2.5B Opportunity - Stock Titan
Sunshine Biopharma (SBFM) Launches Generic Everolimus in Canada - GuruFocus
Sunshine Biopharma stock hits 52-week low at $1.24 - Investing.com Australia
Sunshine Biopharma stock hits 52-week low at $1.24 By Investing.com - Investing.com India
Sunshine Biopharma (NASDAQ:SBFMW) Trading Down 10.9% – Here’s Why - Defense World
Sunshine Biopharma stock hits 52-week low at $1.85 amid steep decline By Investing.com - Investing.com South Africa
Sunshine Biopharma Closes $2.46 Million Direct Offering - TipRanks
Sunshine Biopharma Secures $2.46 Million in Direct Offering - TipRanks
Sunshine Biopharma Closes $2.5 Million Direct Offering - MarketScreener
Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering - ACCESS Newswire
1.05%
0.60%
자본화:
|
볼륨(24시간):